September 25, 2017 / 12:07 PM / 3 months ago

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

Sept 25 (Reuters) - Bristol-Myers Squibb Co

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

* Infinity Pharmaceuticals Inc - ‍combination dose-escalation is also ongoing, and combination expansion is expected to begin in second half of 2017​

* Infinity Pharmaceuticals Inc - ‍patient enrollment is complete in monotherapy dose-escalation, and monotherapy expansion is ongoing​

* Infinity Pharmaceuticals- deal expands Phase 1/1b study to include patients with triple negative breast cancer who havent been previously exposed to anti-PD-1/anti-PD-l1 therapy​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below